AbbVie UK Publishes 2019 Transparency Data; Supporting Collaboration of Medical Opinion Towards Advancing Patient Care and the Development of New Medicines
Maidenhead, UK, 30 June 2020 – Each year AbbVie discloses individual and aggregated transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs) to the Association of the British Pharmaceutical Industry (ABPI).
Due to the unprecedented demands on the NHS as a result of the COVID-19 pandemic, the ABPI provided guidance to companies to submit only their aggregated transfers of value data for 2019 for publication on its central platform, Disclosure UK, and to publish their disaggregated data on their company websites. AbbVie has adopted this guidance and our disaggregated data is available at http://eutransparency.abbvie.com/2019_AbbVie_UK_EFPIA_Report_Final.pdf. We will work with and be guided by the ABPI as it continues to explore how the full disaggregated 2019 data can be submitted to Disclosure UK in line with data from previous years.
We are pleased to confirm that 71% of healthcare professionals who received sponsorship, fees or ‘in-kind’ support from AbbVie in 2019, opted-in for their individual data to be made public.
The collaboration of medical opinion is essential to advance patient care, gain insights into unmet medical needs and progress the development of new medicines. We believe interactions with HCPs, HCOs and patient organisations bring value to patient care.
AbbVie is proud of its collaboration with HCPs and HCOs which has contributed to delivering innovative medicines and has changed the way many diseases impact on patients’ lives. Open communication about these interactions increases understanding of this important collaboration.
Overall, the total sum that AbbVie invested in 2019 in working with and supporting UK healthcare organisations and healthcare professionals is £9.4 m. Of this figure, nearly 63% is on the administration of clinical trials – demonstrating the enduring importance of the UK as a centre of excellence in the development of new medicines.
Note to editors:
1.AbbVie’s acquisition of Allergan completed in Q2, 2020. As such, Allergan and AbbVie will maintain separate reporting mechanisms in respect of their 2019 transfers of value to HCOs, HCPs and patient organisations.
2.AbbVie’s transparency disclosure methodological notes for 2019 can be accessed at http://eutransparency.abbvie.com/2019_AbbVie_UK_Supporting_Document_Final.pdf